Schedule 13G ownership disclosure
Lexeo Therapeutics Inc
Common Stock, $0.0001 par value per share · CUSIP: 52886X107
Event date: 2024-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Omega Fund VI, L.P.
Shares: 1,184,636 · Class: 3.6%
- Omega Fund VI GP, L.P.
Shares: 1,184,636 · Class: 3.6%
- Omega Fund VI GP Manager, Ltd.
Shares: 1,184,636 · Class: 3.6%
- Claudio Nessi
Shares: 1,184,636 · Class: 3.6%
- Otello Stampacchia
Shares: 1,184,636 · Class: 3.6%
- Francesco Draetta
Shares: 1,184,636 · Class: 3.6%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-020474
- Form type
- SCHEDULE 13G/A
- Filer
- Lexeo Therapeutics, Inc.
- CIK
- CIK 1907108
- Filed
- Feb 14, 2025
- Reporting period
- Dec 31, 2024
- Description
- Schedule 13G beneficial ownership